Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 12/20 | 0.44 |
| ▸ | F2 | P00734 | 10/20 | 0.44 |
| ▸ | CTRC | Q99895 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3578767 | 1.00 | PRSS1 (0.44) | PRSS1F2CTRC | |
| SCHEMBL6672676 | 0.98 | PRSS1 (0.46) | PRSS1F2CTRC | |
| SCHEMBL7886105 | 0.98 | PRSS1 (0.46) | PRSS1F2CTRC | |
| SCHEMBL6668341 | 0.98 | PRSS1 (0.46) | PRSS1F2CTRC | |
| SCHEMBL6668345 | 0.98 | PRSS1 (0.46) | PRSS1F2CTRC | |
| SCHEMBL25724111 | 0.75 | PRSS1 (0.42) | PRSS1F2CTRC | |
| SCHEMBL5529318 | 0.74 | PRSS1 (0.44) | PRSS1F2CTRC | |
| SCHEMBL2954265 | 0.70 | PRSS1 (0.36) | PRSS1F2CTRC | |
| SCHEMBL4046976 | 0.70 | PRSS1 (0.36) | PRSS1F2CTRC | |
| SCHEMBL20617569 | 0.70 | PRSS1 (0.36) | PRSS1F2CTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048545-A1 | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity | INNODIA INC. (CA) | 2010-02-25 | — | — | US | disclosed |
| US-20060223884-A1 | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes | INVESTISSEMENT QUEBEC (CA) | 2006-10-05 | — | — | US | disclosed |
| US-20060199853-A1 | Analogs of 4-hydroxyisoleucine and uses thereof | UNIVERSITE LOUIS PASTEUR STRASBOURG I (FR) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223884-A1 | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes | GPR119, HSD3B1, PC | PRSS1 825/4885F2 1378/4885CTRC 3415/4885 |
| US-20060199853-A1 | Analogs of 4-hydroxyisoleucine and uses thereof | GPR119, SLC2A1, SLC5A1 | PRSS1 934/4885F2 2366/4885CTRC 4433/4885 |
| US-20100048545-A1 | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity | LIPC, PC, LIPE | PRSS1 1631/4885F2 1099/4885CTRC 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.